

**Workgroup on
Integrating Cost-Effective Analysis into Clinical Research**

**National Institute of Nursing Research
National Institutes of Health**

**Natcher Center, Bethesda, Maryland
July 17-18, 2008**

Agenda

July 17, 2008

8:15 - 9:00 am Light Refreshments and Registration

9:00 - 9:15 am Welcome & Opening Remarks
Dr. Patricia Grady
Director, NINR

9:15 - 9:30 am Overview & Purpose of the Workgroup
Drs. Paul Cotton & Karen Huss

Challenges in Use of Cost-Effectiveness Analysis

Coordinator: Dr. Cotton

9:30 - 10:00 am What is Cost Effectiveness Analysis and why is it important?

10:00 - 10:30 am Overview of Cost-Effectiveness Analysis in Clinical Research

10:30 - 11:00 am Trends and Issues to Applying Cost-Effectiveness Analysis:

11:00 – 11:20 am Break

11:20 11- 50 am Applying Cost Effectiveness Analysis:
The Case of Rare Diseases

11:50 - 12: 20 How to Assemble an Interdisciplinary Team to Perform Cost-Effectiveness
Analysis for Biobehavioral Interventions

11:55 - 12: 30 am Response & Discussion

12:30 - 1:45 pm	Lunch
1:45 - 2:15 pm	Cost Effectiveness Analysis and the Policy Making Process
2:15 – 3:15 pm	Working Groups/ Small Group Sessions
3:15 - 3:30pm	Integration of Working Groups/ Small Group Sessions
3:30- 4:00 pm	Cost Utility Analysis
<u>Challenges in Research Design and Measurement</u>	
Coordinator: Dr. Huss	
4:00 - 4:30 pm	Health Benefit Valuation and Discounting
4:30 - 4:45 pm	Break
4:45 - 5:15 pm	Identification of Strategies to integrate Cost-Effectiveness Analysis into research
5:15 - 5:45 pm	Discussion Summary of Day 1

July 18, 2008

Challenges in Research Design and Measurement Cont'd.
Coordinator: Dr. Huss

8:15 - 9:00 am	Light Refreshments
9:00 - 9:30 am	Measuring Cost and Inflation Over Time
9:30 - 9:45 am	Discussion
9:45 - 10:15 am	Designing Cost-Effectiveness Analysis Clinical Interventions: Methodological Considerations
10:15 -11:15 am	Working Groups/ Small Group Sessions
11:15 - 11:30 am	Integration of Working Groups/ Small Group Sessions
11:30 - 11:45 am	BREAK
11:45 - 12:45 pm	Future Directions for Research (30- Minute Panel Discussion)

Discussion - All

12:45 - 1:15 pm

Final Questions & Answers

Workgroup

Integrating Cost-Effective Analysis into Clinical Research

National Institute of Nursing research

National Institutes of Health

July 17-18, 2008

Objectives:

The overall objectives of this workgroup are to: (1) improve the participants understanding of the importance of cost-effectiveness analysis; and (2) identify tools to integrate cost-effectiveness analysis into clinical research.

Goals:

Specific goals include: 1) discuss current knowledge related to cost-effectiveness analysis; (2) strategize next steps for incorporating cost-effectiveness analysis in clinical interventions to provide recommendations that will promote the development of a research agenda.

Background:

Because any single rare disease occurs in a small number of patients (< 200,000), the economic impact is surmised to be less than another illness that affects a wider population. However, with over 6,000 rare diseases identified in the United States, this group of disorders may pose a significant societal burden. Rare diseases are often associated with disability, loss of role and employment status, chronic morbidity,

and early mortality requiring the extended use of expensive treatment modalities. New health care technologies and interventions, including interventions for self-management, for rare diseases are emerging. Thus, it will be important to develop the capacity to identify technologies and interventions that maximize health outcomes and optimize the cost-benefit ratio. Rare disease experts such as the 2004 NINR sponsored working group on “Increasing Opportunities in Clinical Research: Expert Working Group Utilizing Allergic Bronchopulmonary Aspergillosis as a Framework” have recommended increased attention to the economic impact of rare diseases for both the individual and society. Therefore, a research agenda focused on cost-effective analysis (CEA) will be a critical step in shaping future policy initiatives to support the allocation of scarce health resources for the treatment of rare diseases. Integrating cost-effectiveness with evaluation of biobehavioral interventions promotes a research agenda of long standing interest to the NINR.

Format: Solicited paper presentations on agenda topics; Responses and Discussion